"Its popularity is due, in large part, to its promotion by celebrities and influencers, but also to massive controversial advertising campaigns. Ozempic and other similar drugs, known as GLP-1 agonists, mimic a hormone that regulates blood glucose by inducing increased insulin secretion from the pancreas. This slows the rate that food leaves the stomach and enters the intestines, giving a feeling of satiety that reduces appetite and can consequently lead to weight loss."
"The U.S. continues to be the country with the highest consumption of weight-loss drugs, although their consumption is also growing in Europe. In pharmacies in Spain, sales of Ozempic, Wegovy and Mounjaro exceeded 4.8 million packages in 2024, a 51% increase on previous year. A 2023 report by Morgan Stanley estimated that 24 million people in the United States 7% of the population would take LPG-1 by 2035 and warned of its possible impact on the food industry and hospitality sector."
Some restaurants in New York have reduced portions and adapted menus to customers taking Ozempic. Ozempic, prescribed for type 2 diabetes, reduces appetite by slowing gastric emptying and increasing insulin secretion through GLP-1 mechanisms. These drugs also act on the central nervous system and alter food cravings, with users reporting diminished mental noise around eating. Use is highest in the U.S. and growing in Europe; Spain sales jumped 51% in 2024. Financial analysts project millions more users by 2035 and anticipate industry effects driven further by upcoming pill formats and less frequent dosing.
Read at english.elpais.com
Unable to calculate read time
Collection
[
|
...
]